Common Stock, par value $0.0001 per share
- Symbol
- BJDX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Bluejay Diagnostics, Inc.
BJDXNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 13, 2026, Bluejay Diagnostics, Inc. issued a press release regarding, among other things, the completion of certain manufacturing-related contractual obligations.…
Company context
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™ can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Current securities
Registered securities in this filing
BLUEJAY DIAGNOSTICS, INC. · 8-K · Filed 2026-10-13
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
October 13, 2026, Bluejay Diagnostics, Inc. issued a press release regarding, among other things, the completion of certain manufacturing-related
contractual obligations.
The
information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed”
for the purpose of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing under the
Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
99.1 Press Release, dated October 13, 2026.
104 Cover Page Interactive Data
File (embedded within the Inline XBRL document).
Filed exhibits (1)
Exhibit 99.1 Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, Mass. October 13, 2026 - Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that it has completed the establishment of a manufacturing site for Symphony™ cartridges, achieving a critical contractual milestone as the Company advances toward regulatory submission and potential commercialization. The milestone was achieved ahead of the October 23, 2026 contractual deadline established under Bluejay’s amended license agreement with Toray Industries, Inc. (“Toray”). Bluejay has formally notified Toray that the Company has fulfilled its obligation to substantially complete establishment of a manufacturing site. Bluejay’s manufacturing strategy is being developed around complementary manufacturing capabilities at SanyoSeiko Co., Ltd. in Japan and ALURIS Sciences, (previously Argonaut Manufacturing Se…
Open exhibit ↗